Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: An analysis from the OpT2mise randomized trial

Muriel Metzger, Javier Castañeda, Yves Reznik, Francesco Giorgino, Ignacio Conget, Ronnie Aronson, Simona de Portu, Sarah Runzis, Scott W. Lee, Ohad Cohen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

This analysis investigated factors associated with the decrease in HbA1c in patients receiving continuous subcutaneous insulin infusion (CSII) in the OpT2mise randomized trial. In this study, patients with type 2 diabetes and HbA1c >8% following multiple daily injections (MDI) optimization were randomized to receive CSII (n = 168) or MDI (n = 163) for 6 months. Patient-related and treatment-related factors associated with decreased HbA1c in the CSII arm were identified by univariate and multivariate analyses. CSII produced a significantly greater reduction in HbA1c than MDI, and the treatment difference increased with baseline HbA1c. In the CSII arm, the only factors significantly associated with decreased HbA1c were higher baseline HbA1c (P <.001), geographical region (P <.001), higher educational level (P =.012), higher total cholesterol level (P =.002), lower variability of baseline glucose values on continuous glucose monitoring (P <.001) and the decrease in average fasting self-monitored blood glucose at 6 months (P <.001). These findings suggest that CSII offers an option to improve glycemic control in a broad range of patients with type 2 diabetes in whom control cannot be achieved with MDI. OpT2mise ClinicalTrials.gov number: NCT01182493 (https://clinicaltrials.gov/).

Original languageEnglish
Pages (from-to)1490-1494
Number of pages5
JournalDiabetes, Obesity and Metabolism
Volume19
Issue number10
DOIs
StatePublished - Oct 2017
Externally publishedYes

Funding

FundersFunder number
Becton Dickenson
Eli Lilly and Lifescan
John Shin and Severine Liabat
Medtronic International Trading Sàrl
Eli Lilly and Company
Bayer
GlaxoSmithKline
Sanofi
Medtronic
Takeda Pharmaceutical Company
Novo Nordisk

    Keywords

    • blood glucose self-monitoring
    • glycated hemoglobin
    • insulin infusion systems
    • insulin therapy
    • multiple daily injections
    • type 2 diabetes mellitus

    Fingerprint

    Dive into the research topics of 'Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: An analysis from the OpT2mise randomized trial'. Together they form a unique fingerprint.

    Cite this